Steven Cohen’s ADMA Biologics ADMA Stock Holding History

Steven Cohen’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$419K	Buy	50,100 +29,200	+140%	+$266K	﹤0.01%	3251
2026 Q1	$188K	Sell	20,900 -26,300	-56%	-$415K	﹤0.01%	3538
2025 Q4	$861K	Buy	+47,200	New	+$796K	﹤0.01%	2950
2025 Q2	–	Sell	-300,000	Closed	-$5.95M	–	2131
2025 Q1	$5.95M	Buy	+300,000	New	+$5.19M	0.01%	862

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Steven Cohen's ADMA Position: Q2 2026 in Review

Steven Cohen reduced its ADMA Biologics (ADMA) stake by 87% in Q2 2026, selling an estimated $26.2M and leaving 413,935 shares worth $3.46M. The position accounts for ﹤0.01% of the portfolio, ranked #2028.

Steven Cohen first reported a position in ADMA in Q1 2020 and has held it in 12 quarters since. The position peaked at $29.6M in Q1 2026. 321 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

Steven Cohen held 413,935 shares of ADMA Biologics worth $3.46M as of Q2 2026.
Steven Cohen sold 2,874,822 ADMA Biologics shares in Q2 2026, an estimated $26.2M.
ADMA Biologics made up ﹤0.01% of Steven Cohen's portfolio in Q2 2026, its #2028 holding.
Steven Cohen first reported a position in ADMA Biologics in Q1 2020 and has held it in 12 quarters since.
Steven Cohen's ADMA Biologics position peaked at $29.6M in Q1 2026.
321 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on Point72 Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.